ADMA denies short seller allegations

ADMA Biologics Inc. (ADMA) faced a short seller report alleging misleading information, leading to a five-day stock decline. The company responded, denying the allegations, which drove a 11.6% stock increase on April 13. Mizuho cut its price target on ADMA from $30 to $24 while maintaining an Outperform rating, citing estimate reductions. Cantor Fitzgerald downgraded ADMA to Neutral from Overweight, citing investor concerns.

The biotech sector, particularly low-priced stocks, was affected. ADMA's stock price volatility and the mixed analyst sentiments led to uncertainty, impacting investor decisions. The denial of allegations temporarily boosted ADMA's stock, but the price target cuts suggest lingering concerns.

Upcoming catalysts to watch include ADMA's earnings release, scheduled for May 10, which will provide updates on its financial health and pipeline progress. Additionally, any further developments or clarifications regarding the short seller allegations will impact ADMA's stock performance.